Predicting Parkinson's Disease (PD) progression is crucial, and voice biomarkers offer a non-invasive method for tracking symptom severity (UPDRS scores) through telemonitoring. Analyzing this longitudinal data is challenging due to within-subject correlations and complex, nonlinear patient-specific progression patterns. This study benchmarks LMMs against two advanced hybrid approaches: the Generalized Neural Network Mixed Model (GNMM) (Mandel 2021), which embeds a neural network within a GLMM structure, and the Neural Mixed Effects (NME) model (Wortwein 2023), allowing nonlinear subject-specific parameters throughout the network. Using the Oxford Parkinson's telemonitoring voice dataset, we evaluate these models' performance in predicting Total UPDRS to offer practical guidance for PD research and clinical applications.

Disease progression models infer group-level temporal trajectories of change in patients' features as a chronic degenerative condition plays out. They provide unique insight into disease biology and staging systems with individual-level clinical utility. Discrete models consider disease progression as a latent permutation of events, where each event corresponds to a feature becoming measurably abnormal. However, permutation inference using traditional maximum likelihood approaches becomes prohibitive due to combinatoric explosion, severely limiting model dimensionality and utility. Here we leverage ideas from optimal transport to model disease progression as a latent permutation matrix of events belonging to the Birkhoff polytope, facilitating fast inference via optimisation of the variational lower bound. This enables a factor of 1000 times faster inference than the current state of the art and, correspondingly, supports models with several orders of magnitude more features than the current state of the art can consider. Experiments demonstrate the increase in speed, accuracy and robustness to noise in simulation.

Chronic diseases often progress differently across patients. Rather than randomly varying, there are typically a small number of subtypes for how a disease progresses across patients. To capture this structured heterogeneity, the Subtype and Stage Inference Event-Based Model (SuStaIn) estimates the number of subtypes, the order of disease progression for each subtype, and assigns each patient to a subtype from primarily cross-sectional data. It has been widely applied to uncover the subtypes of many diseases and inform our understanding of them. But how robust is its performance? In this paper, we develop a principled Bayesian subtype variant of the event-based model (BEBMS) and compare its performance to SuStaIn in a variety of synthetic data experiments with varied levels of model misspecification. BEBMS substantially outperforms SuStaIn across ordering, staging, and subtype assignment tasks. Further, we apply BEBMS and SuStaIn to a real-world Alzheimer's data set. We find BEBMS has results that are more consistent with the scientific consensus of Alzheimer's disease progression than SuStaIn.

Alzheimer's disease (AD), a degenerative brain condition, can benefit from early prediction to slow its progression. As the disease progresses, patients typically undergo brain atrophy. Current prediction methods for Alzheimers disease largely involve analyzing morphological changes in brain images through manual feature extraction. This paper proposes a novel method, the Deformation-Aware Temporal Generative Network (DATGN), to automate the learning of morphological changes in brain images about disease progression for early prediction. Given the common occurrence of missing data in the temporal sequences of MRI images, DATGN initially interpolates incomplete sequences. Subsequently, a bidirectional temporal deformation-aware module guides the network in generating future MRI images that adhere to the disease's progression, facilitating early prediction of Alzheimer's disease. DATGN was tested for the generation of temporal sequences of future MRI images using the ADNI dataset, and the experimental results are competitive in terms of PSNR and MMSE image quality metrics. Furthermore, when DATGN-generated synthetic data was integrated into the SVM vs. CNN vs. 3DCNN-based classification methods, significant improvements were achieved from 6. 21\% to 16\% in AD vs. NC classification accuracy and from 7. 34\% to 21. 25\% in AD vs. MCI vs. NC classification accuracy. The qualitative visualization results indicate that DATGN produces MRI images consistent with the brain atrophy trend in Alzheimer's disease, enabling early disease prediction.

Disease progression models infer group-level temporal trajectories of change in patients' features as a chronic degenerative condition plays out.

Chronic Kidney Disease (CKD) affects nearly 10\% of the global population and often progresses to end-stage renal failure. Accurate prognosis prediction is vital for timely interventions and resource optimization. We present a transformer-based framework for predicting CKD progression using multi-modal electronic health records (EHR) from the Seoul National University Hospital OMOP Common Data Model. Our approach (\textbf{ProQ-BERT}) integrates demographic, clinical, and laboratory data, employing quantization-based tokenization for continuous lab values and attention mechanisms for interpretability. The model was pretrained with masked language modeling and fine-tuned for binary classification tasks predicting progression from stage 3a to stage 5 across varying follow-up and assessment periods. Evaluated on a cohort of 91,816 patients, our model consistently outperformed CEHR-BERT, achieving ROC-AUC up to 0.995 and PR-AUC up to 0.989 for short-term prediction. These results highlight the effectiveness of transformer architectures and temporal design choices in clinical prognosis modeling, offering a promising direction for personalized CKD care.

Interstitial lung disease (ILD) is a leading cause of morbidity and mortality in systemic sclerosis (SSc). Chest computed tomography (CT) is the primary imaging modality for diagnosing and monitoring lung complications in SSc patients. However, its role in disease progression and mortality prediction has not yet been fully clarified. This study introduces a novel, large-scale longitudinal chest CT analysis framework that utilizes radiomics and deep learning to predict mortality associated with lung complications of SSc. We collected and analyzed 2,125 CT scans from SSc patients enrolled in the Northwestern Scleroderma Registry, conducting mortality analyses at one, three, and five years using advanced imaging analysis techniques. Death labels were assigned based on recorded deaths over the one-, three-, and five-year intervals, confirmed by expert physicians. In our dataset, 181, 326, and 428 of the 2,125 CT scans were from patients who died within one, three, and five years, respectively. Using ResNet-18, DenseNet-121, and Swin Transformer we use pre-trained models, and fine-tuned on 2,125 images of SSc patients. Models achieved an AUC of 0.769, 0.801, 0.709 for predicting mortality within one-, three-, and five-years, respectively. Our findings highlight the potential of both radiomics and deep learning computational methods to improve early detection and risk assessment of SSc-related interstitial lung disease, marking a significant advancement in the literature.

Paediatric kidney disease varies widely in its presentation and progression, which calls for continuous monitoring of renal function. Using electronic health records collected between 2019 and 2025 at Great Ormond Street Hospital, a leading UK paediatric hospital, we explored a temporal modelling approach that integrates longitudinal laboratory sequences with demographic information. A recurrent neural model trained on these data was used to predict whether a child would record an abnormal serum creatinine value within the following thirty days. Framed as a pilot study, this work provides an initial demonstration that simple temporal representations can capture useful patterns in routine paediatric data and lays the groundwork for future multimodal extensions using additional clinical signals and more detailed renal outcomes.